SAN FRANCISCO, March 3,
2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR)
is scheduled to present at the upcoming Cowen and Company
36th Annual Health Care Conference in Boston, Massachusetts on Wednesday, March 9, 2016 at 8:40 a.m. Eastern time.
The presentation will be accessible via a Webcast through a link
posted on the Investor Relations, Events Calendar section of the
Nektar website: http://www.nektar.com. This Webcast will be
available for replay until April 10,
2016.
About Nektar
Nektar Therapeutics has a robust R&D pipeline in pain,
oncology, hemophilia and other therapeutic areas. In the area of
pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved
once-daily oral peripherally-acting mu-opioid receptor antagonist
(PAMORA) medication for the treatment of opioid-induced
constipation (OIC), in adult patients with chronic, non-cancer
pain. The product is also approved in the European Union as
MOVENTIG® (naloxegol) and is indicated for adult patients with OIC
who have had an inadequate response to laxatives. The AstraZeneca
agreement also includes NKTR-119, an earlier stage development
program that is a co-formulation of MOVANTIK and an opioid.
NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic
pain conditions, is in Phase 3 development. In hemophilia, Nektar
has a collaboration agreement with Baxalta for ADYNOVATE™
[Antihemophilic Factor (Recombinant)], a longer-acting PEGylated
Factor VIII therapeutic approved in the U.S. in patients over 12
with hemophilia A. In anti-infectives, Amikacin Inhale is in Phase
3 studies conducted by Bayer Healthcare as an adjunctive treatment
for intubated and mechanically ventilated patients with
Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
AstraZeneca's MOVANTIK™, Baxalta's ADYNOVATE™, UCB's CIMZIA® for
Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for
hepatitis C, and Amgen's NEULASTA® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE™ is a trademark of Baxalta Inc.
Contact:
For Investors and Media:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Jodi Sievers of Nektar Therapeutics
415-482-5593
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-present-at-cowen-and-companys-36th-annual-health-care-conference-in-boston-ma-300230514.html
SOURCE Nektar Therapeutics